03.13.2018 Issue 393

   
Visit HealthEconomics.Com Subscribe to Newsletters  |  Contact Us  |  Forward to a Friend
Sponsored by:

This Week's HEOR Round-up
The Top Story in HEOR: Latest Headlines in HEOR:

ICER Updates Value-based Price
Benchmark for Alirocumab

Monday, March 12, 2018

The Institute for Clinical and Economic Review (ICER) today released a Preliminary New Evidence Update for alirocumab (Praluent, Regeneron/Sanofi), based on results from the ODYSSEY outcomes trial presented at this weekend’s American College of Cardiology’s 2018 Scientific Session.

UnitedHealthcare to Expand Rebates to 7 Million Enrollees

Gottlieb: ‘Rigged Payment Scheme’ Blocks Access to Low-Cost Drugs

CMS Changes to Rating System Results in More 5-Star Hospitals

Opinion: ACA is Flawed, but Lawsuits Could Set Back Health System

AMCP Announces New Benefit with UF College of Pharmacy

Blog Post: Trump Proposal Would Hurt Medicare Beneficiaries in Part D “Donut Hole”

Medtronic Moves Closer to Value-Based Care

Health Economist Issues Warning on Biosimilar Savings

AI Companies Make Headlines at HIMSS18


Associate Director, Field HEOR - Managed Care (Colorado)

Senior Research Analyst - ID: 127317BR

Associate Director, Strategic Market Access- CAR-T

Associate Healthcare Outcomes Solutions Director

Market Access / Health Economics Manager, Ireland. €50k-€60k

Health Economics and Market Access (Senior) Consultant, Cambridge, UK

Research Scientist - Outcomes Research/Health Preferences

Industry Spotlight



Conferences Webinars

6th Annual Patient Adherence and Engagement Summit
    March 19-21, Philadelphia

14th Life Sciences Accounting & Reporting Congress
    March 19-21, Philadelphia

6th Annual Patient Advocacy Summit
    March 19-21, Philadelphia

18th Population Health Colloquium
    March 19-21, Philadelphia

Essential Elements of Pricing
    March 20-21, Durham, NC

Bringing the Inside Out: Chart Abstraction Methodologies that Integrate Physician Insights
    March 13

Tailored to Translate: Custom Preclinical Models for Advancing Diverse Therapeutic Strategies in Oncology
    March 14

EVDAS Outputs are Available to MAHs – What Now?
    March 15

Expert Committees – Powerful Platforms for Clinical Trial Transformation
    March 15


Conference of the Week Webinar of the Week Job of the Week Link of the Week

Syndicated Reports White Papers
Biosimilars: E.U. Payer Perspectives

MSL Teams: Field Force Size and Structure

Market Access Impact: Type 2 Diabetes Mellitus (Injectables) (US) 2017

Market Access Impact: Type 2 Diabetes Mellitus (Orals) (US) 2017

Market Access Impact: Rheumatoid Arthritis (US) 2017

Reforming Biopharmaceutical Pricing at Home and Abroad

U.S. Presidential Mandate on Value-based Drug Pricing: Moonshot or Wormhole?

The State of Digital Identification and Signatures

Secure Document Workflows in Drug Development

Streamline Regulatory Compliance in Life Sciences with Digital Transaction Management


Special Thanks to Our Partners:
Evidence Partners   Evidera    G&J Lee RecruitmentHealthCoreMAPS
      University of FL        Truven    XcendaOM1Parexel
ICON    Jefferson  Dymaxium    Curo
    PharmeritDRG AbacuseMax Health